- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13.11.24 | J&J's nipocalimab granted FDA breakthrough designation for Sjögren's disease | ||
| 12.11.24 | Novavax announces FDA clinical hold lift on phase 3 COVID-19/flu vaccine study | ||
| 12.11.24 | J&J submits EU and US applications for subcutaneous Darzalex in smouldering multiple myeloma | ||
| 12.11.24 | Ogilvy appoints Mario Muredda as global chief executive officer of Ogilvy Health | ||
| 11.11.24 | FDA approves Autolus' Aucatzyl to treat acute lymphoblastic leukaemia | ||
| 11.11.24 | Daiichi Sankyo enters $300m licensing deal with Alteogen to develop subcutaneous Enhertu | ||
| 11.11.24 | AstraZeneca/Amgen's Tezspire shows promise in phase 3 CRSwNP trial | ||
| 08.11.24 | WHO announces priority endemic pathogens for urgent vaccine development | ||
| 08.11.24 | UK study shows RSV vaccine could reduce antibiotic use and antimicrobial resistance | ||
| 08.11.24 | NICE recommends Blueprint Medicines' Ayvakyt to treat rare blood disorder | ||
| 07.11.24 | Sanofi/Regeneron's Dupixent approved by EC for younger eosinophilic oesophagitis patients | ||
| 07.11.24 | Novo Nordisk and Ascendis enter $285m partnership for once-monthly GLP-1 drug | ||
| 07.11.24 | Chiesi and Oak Hill enrol first European patient in phase 2b premature birth study | ||
| 06.11.24 | Johnson & Johnson's Balversa granted MHRA approval in bladder cancer | ||
| 06.11.24 | FDA approves Journey Medical's Emrosi to treat inflammatory lesions of rosacea | ||
| 06.11.24 | GCI Health appoints Annalise Coady as president, UK market lead and EMEA head of growth | ||
| 05.11.24 | AstraZeneca's Fasenra approved by EC to treat rare inflammatory disease EGPA | ||
| 05.11.24 | GSK expands immunology pipeline by acquiring Chimagen's CMG1A46 in deal worth $850m | ||
| 05.11.24 | UCB shares 'encouraging' data for Alzheimer's disease candidate bepranemab | ||
| 04.11.24 | Novo Nordisk's semaglutide shows promise in fatty liver disease MASH | ||
| 04.11.24 | LEO Pharma shares final long-term results for atopic dermatitis drug Adbry | ||
| 04.11.24 | MHRA approves CStone Pharmaceuticals' sugemalimab to treat lung cancer in adults | ||
| 04.11.24 | Countdown to an optimised drug launch: five determinants of success | ||
| 01.11.24 | Novartis' Scemblix granted FDA accelerated approval in newly diagnosed CML | ||
| 01.11.24 | Dermavant reports positive long-term results for Vtama cream in atopic dermatitis |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
